Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS mutation
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
Oncomine™ Dx Target Test (10)
Idylla™ ctKRAS Mutation Test
Lung Cancer 8-Gene Kit
Oncomine™ Dx Target Test (10)
Idylla™ ctKRAS Mutation Test
Lung Cancer 8-Gene Kit
Associations
(239)
News
Trials
Search handles
@ADesaiMD
@APassaroMD
@AndresC27622123
@AndresFCardonaZ
@ArndtVogel
@BenWestphalen
@BiagioMd
@BijoyTelivala
@BrendonStilesMD
@BurrisSkip
@CharuAggarwalMD
@CyclingDoctor
@DKirschMDPhD
@DanZhaoMD
@DocJZ
@DocMCotant
@DrBonillaOnc
@DrChoueiri
@DrEzraCohen
@DrJNaidoo
@DrMarkAwad
@DrRanaMcKay
@DrSanjayPopat
@DrShubhamPant
@DrSteveMartin
@DrVijayPatil11
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@DucreuxMichel
@EnriqueSoto8
@FASinicropeMD
@FAndreMD
@FawziAbuRous
@FogacciJoao
@FordePatrick
@GIcancerDoc
@GPentheroudakis
@GRecondoMD
@GlopesMd
@HHorinouchi
@HenningWillers
@IbrahimSahinMD1
@Inma__Gallego
@IvyLorena_Md
@JFabianMH
@JPatelMD
@JackWestMD
@Jbauml
@Joshua_Reuss
@JulienMazieres
@KrishanJethwa
@Kristel_GT
@Latinamd
@LeciaSequist
@LuisLara_M
@MDuruisseaux
@MLPOncoData
@MPishvaian
@ManuelDomine
@Martin_AngelMD
@Myeloma_Doc
@NievesM42607618
@NitinJainMD
@PatelOncology
@PatrickCMa1
@PatrickHwuMD
@PeterHoseinMD
@RManochakian
@RachelRiechelm2
@RachelSanbornMD
@RielyMD
@Rndubois
@SLentzsch
@SalemGIOncDoc
@SamtaniSuraj
@ShaalanBeg
@ShepardDale
@StephenVLiu
@SuyogCancer
@TaylorJ_MD
@TejasPatilMD
@UmutDisel
@VamsiVelcheti
@VanMorrisMD
@VanitaNoronha
@VikasSinghMD
@VivekSubbiah
@VoglNY
@YJanjigianMD
@barriere_dr
@benweinbergmd
@bin_abeid
@bpiperdi
@cancerassassin1
@cczielinski
@cdanicas
@chadinabhan
@christine_lovly
@chulkimMD
@cinthiavgauna
@davidhenrymd
@diegoadiazg
@dipeshuprety4
@doctorC369
@doctorpemm
@dr_yakupergun
@drallysonocean
@drgandara
@drjasonstarr
@drjgauthier
@drkpavithran
@elmodir
@g_mountzios
@gabe_a_brooks
@gary_lyman
@giusvisc
@jamecancerdoc
@jonathanloree
@jsoriamd
@lindamahj
@malkadav
@marklewismd
@mgfakih
@n8pennell
@notahedge
@ogarrieta
@oncoOuLungCA
@pashtoonkasi
@profghjackson
@rbryanbell
@rschilsky
@singhv2003
@tmprowell
@weldeiry
Search handles
@ADesaiMD
@APassaroMD
@AndresC27622123
@AndresFCardonaZ
@ArndtVogel
@BenWestphalen
@BiagioMd
@BijoyTelivala
@BrendonStilesMD
@BurrisSkip
@CharuAggarwalMD
@CyclingDoctor
@DKirschMDPhD
@DanZhaoMD
@DocJZ
@DocMCotant
@DrBonillaOnc
@DrChoueiri
@DrEzraCohen
@DrJNaidoo
@DrMarkAwad
@DrRanaMcKay
@DrSanjayPopat
@DrShubhamPant
@DrSteveMartin
@DrVijayPatil11
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@DucreuxMichel
@EnriqueSoto8
@FASinicropeMD
@FAndreMD
@FawziAbuRous
@FogacciJoao
@FordePatrick
@GIcancerDoc
@GPentheroudakis
@GRecondoMD
@GlopesMd
@HHorinouchi
@HenningWillers
@IbrahimSahinMD1
@Inma__Gallego
@IvyLorena_Md
@JFabianMH
@JPatelMD
@JackWestMD
@Jbauml
@Joshua_Reuss
@JulienMazieres
@KrishanJethwa
@Kristel_GT
@Latinamd
@LeciaSequist
@LuisLara_M
@MDuruisseaux
@MLPOncoData
@MPishvaian
@ManuelDomine
@Martin_AngelMD
@Myeloma_Doc
@NievesM42607618
@NitinJainMD
@PatelOncology
@PatrickCMa1
@PatrickHwuMD
@PeterHoseinMD
@RManochakian
@RachelRiechelm2
@RachelSanbornMD
@RielyMD
@Rndubois
@SLentzsch
@SalemGIOncDoc
@SamtaniSuraj
@ShaalanBeg
@ShepardDale
@StephenVLiu
@SuyogCancer
@TaylorJ_MD
@TejasPatilMD
@UmutDisel
@VamsiVelcheti
@VanMorrisMD
@VanitaNoronha
@VikasSinghMD
@VivekSubbiah
@VoglNY
@YJanjigianMD
@barriere_dr
@benweinbergmd
@bin_abeid
@bpiperdi
@cancerassassin1
@cczielinski
@cdanicas
@chadinabhan
@christine_lovly
@chulkimMD
@cinthiavgauna
@davidhenrymd
@diegoadiazg
@dipeshuprety4
@doctorC369
@doctorpemm
@dr_yakupergun
@drallysonocean
@drgandara
@drjasonstarr
@drjgauthier
@drkpavithran
@elmodir
@g_mountzios
@gabe_a_brooks
@gary_lyman
@giusvisc
@jamecancerdoc
@jonathanloree
@jsoriamd
@lindamahj
@malkadav
@marklewismd
@mgfakih
@n8pennell
@notahedge
@ogarrieta
@oncoOuLungCA
@pashtoonkasi
@profghjackson
@rbryanbell
@rschilsky
@singhv2003
@tmprowell
@weldeiry
Filter by
Latest
10ms
Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer https://t.co/G5fIaMjHOe via @onclive (@marciasgreen)
10 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
10ms
Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)
10 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
10ms
Despite the high prevalence of KRAS mutations in pancreatic cancers, a limited number of cases harbor an actionable point mutation. @EileenMOReilly @MSKCancerCenter #pancsm https://t.co/7uqF6ZMfTU (@OncLive)
10 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
10ms
Interested in the latest in #CARTcelltherapy and treatment of HER2+ #esophagogastriccancer and KRAS-G12 C-mutant #NSCLC? You'll find brief summaries of work by @MSKCancerCenter's @jaeparkmd, @YJanjigianMD, @SteveMaronMD, @rohit_thum, + @KCArbourMD here. https://t.co/GDzcsZ7csG (@MSK_DeptOfMed)
10 months ago
CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
10ms
Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer @EileenMOReilly @MSKCancerCenter #pcsm https://t.co/ROtIRmXNMy (@OncLive)
10 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
10ms
Explorations Unearth New Potential of KRAS Mutations in #PancreaticCancer https://t.co/akQ4eEmIq9 Featuring data from #ASCO23 including an early phase KRAS targeted vaccine data in adjuvant setting from Dr. @EileenMOReilly (@Aiims1742)
10 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
10ms
Latest living guideline update on stage IV NSCLC just published. Listen to Dr. @ns_chd share the new updates - including second-line options for patients with EGFR exon 20 insertions or KRAS G12C mutations - & the rationale in our latest podcast episode https://t.co/yIzwf6akKb (@BrittanyEHarvey)
10 months ago
Clinical • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • KRAS G12 • EGFR exon 20 mutation
11ms
👀 Check out what’s popular this week in #JCOPO: Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant #NSCLC ➡️ https://t.co/4pghKnMZFP @rohit_thum @RielyMD @KCArbourMD #lcsm (@JCOPO_ASCO)
11 months ago
Clinical • Real-world evidence • Real-world • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
11ms
Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine https://t.co/36kOZ8bPEi... https://t.co/XyNcxEXxRm Now open @MDAndersonNews 👉🏽 a phase 1b trial of Adagrasib in KRAS G12C mutant #PancreaticCancer https://t.co/whJlkT6aXi (@Aiims1742)
11 months ago
Pan tumor
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
11ms
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 💥KEAP1, SMARCA4 and CDKN2A mutations lead to shorter survival in lung cancer patients treated with KRAS-G12C inhibitors (@mvnegrao et al.) @CD_AACR @MDAndersonNews https://t.co/Vh2FY3pluD https://t.co/EvmUncUHrN (@dr_yakupergun)
11 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
|
KRAS mutation • KEAP1 mutation • CDKN2A mutation • SMARCA4 mutation
11ms
Commentary on @JCO_ASCO paper Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation @GIcancerDoc @Aiims1742 @DrShubhamPant @TumorBoardTues @MPishvaian Thanks to @cczielinski for invite to write the editorial @weoncologists @ESMO_Open https://t.co/erYeW4KdD0 (@VivekSubbiah)
11 months ago
Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
11ms
Great paper from @rohit_thum and @KCArbourMD from @MSK_DeptOfMed @MSKCancerCenter Shows a couple of key findings for patients with KRAS G12C mutated NSCLC treated with sotorasib. https://t.co/QOhzCq4z9i @JCOPO_ASCO (@RielyMD)
11 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
11ms
Are you ready for targeted neoadjuvant therapy for EGFR and KRAS G12C mutant NSCLC? @MNagasaka and @kamarroneMD discuss ongoing trials with these new treatment paradigms. More discussion to come later in the program! #DAVAHawaiiLung https://t.co/CSNPUHba3j (@KE_Gallaway)
11 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
11ms
📢 Pleased to share this link 👇👇 that give you free access to our article "Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer" @JTOonline https://t.co/ag88PwcEVL (@MDuruisseaux)
11 months ago
Adverse events
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
11ms
WATCH: @DrShubhamPant, of @MDAndersonNews, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors. #crcsm https://t.co/H1vDezOWOg (@OncLive)
11 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
11ms
#ILCC23 what to do at the time of PD from acquired resistance in oncogene-driven NSCLC? Empiric or biomarker-related decision making? Is paradigm different for EGFR-mutated vs ALK vs METex14 vs KRAS G12C? Come listen to our panel discussion @HwakeleeMD @DrRoyHerbstYale @gotoPER (@drgandara)
11 months ago
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
11ms
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases @JCO_ASCO #Precisionmedicine https://t.co/hDyyoGFtXh (@VivekSubbiah)
11 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
11ms
Si te perdiste #ASCO23, ya tienes disponibles los video-resúmenes de #LungCancer Updates de la mano del @gecp_org. En este caso, el Dr. @NadalErnest aborda las novedades en: ▶️ CPNM KRAS mutado https://t.co/v78bHIhbjh ▶️ CPNM Driver negativo https://t.co/J68BovSEKp #ASCOUPDATES (@SECTtoracica)
11 months ago
Video
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
11ms
The Role of Driver Mutations in NSCLC Treatment - 2022 Program: LCVL https://t.co/UeZfcTFXBI In this video, Dr. @JackWestMD discusses driver mutations such as KRAS and ALK, and the importance of advocating for targeted therapy for patients with actionable mutations. (@cancerGRACE)
11 months ago
Clinical • Video
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
|
KRAS mutation
12ms
BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12A • KRAS G12 • KRAS G13 • KRAS Q61H • KRAS A146V • KRAS G13C
|
BI-2493
12ms
@DrShubhamPant, a member of our Conquering KRAS in Pancreatic Cancer TeamLab, presented Updates on Abstract 425082: Krystal-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced Solid Tumors Harboring a KRASG12C Mutation. (@break_cancer)
12 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
12ms
@AACR @CCR_AACR 🚨 📚: Early ctDNA changes of KRAS G12C in Phase 2 trial of adagrasib 🧪 for advanced #KRASG12C mutant #LCSM 🩺. @KRASKickers Max response seen in first ~3 weeks 🕐. 89.7% patients showed >90% ctDNA decrease 📉 84.6% achieved complete clearance by cycle 2 🧪.… https://t.co/NPwRU31v6L (@ADesaiMD)
12 months ago
Clinical • Circulating tumor DNA • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
12ms
In a session on #LungCancer at #ASCO23, @LuisPaz_Ares shares biomarker analyses of CodeBreaK 200, a phase 3 trial of investigating pretreated KRAS G12C-mutated advanced #NSCLC: https://t.co/aVVKyvGlF4 #CRUKFunded (@CRUKresearch)
12 months ago
Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
12ms
Always a treat to hear @Aiims1742 describe RAS signalling and differences in KRAS mutant alleles in #PancreaticCancer pathogenesis ➡️ integration of transcriptomics to interrogate TME and metabolomics #abstract4020 ✅ Differences certainly in G12D vs G12R (@graokane)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D
12ms
Destiny -CRC02 Trastuzumab deruxtecan in CRC . For both k ras mutated and wild type . 5.4 mg per kg dose better tolerated Will it make it big in CRC ? @agrothey @GIcancerDoc @MPishvaian @asco @OncoAlert #ASCO23 (@SuyogCancer)
12 months ago
RAS (Rat Sarcoma Virus)
|
KRAS mutation • RAS mutation
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
12ms
Phase 1 Study of NEROFE and doxorubicin in KRAS-mutated ST2- positive solid tumors (TPS2667). @benweinbergmd @chulkimMD @RuthHe12 @mnoel3232 @StephenVLiu @LombardiCancer (@RueschCenter)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
|
doxorubicin hydrochloride • Nerofe (84AA-API 14AA)
12ms
In a first-in-human Phase I study, Dr. Maria Pia Morelli evaluated the safety and efficacy of the Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors (2547).https://t.co/jfW7BFjeFH @mariapiamorell1 @skopetz @ASCO #ASCO23 #EndCancer (3/9) (@MDAndersonNews)
12 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
|
TP53 mutation • KRAS mutation • TP53 mutation + KRAS mutation • KRAS mutation + TP53 mutation
12ms
#KRAS VACCINE strategy may have a possible broad applicability in solid tumors due to KRAS mutational frequency AMPLIFY-201 #ASCO23 @pashtoonkasi (@alfdestefano)
12 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
12ms
"I'm hopeful this is the decade where we finally crack the KRAS code," says Dr. Shubham Pant in his presentation at #ASCO23 about a study he led on adagrasib use in patients with advanced solid tumors with a KRAS mutation. https://t.co/PUUSItVLBL @ASCO @DrShubhamPant #EndCancer (@MDAndersonNews)
12 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
|
Krazati (adagrasib)
12ms
The second @ASCO abstract from @benweinbergmd is "Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors." This found that NEROFE also has been shown to induce microRNA miR-217 which downregulates KRAS and MAPK1/2 gene expression in preclinical models.… https://t.co/GqgfaJC5tj (@CCAlliance)
12 months ago
KRAS (KRAS proto-oncogene GTPase) • MAPK1 (Mitogen-activated protein kinase 1) • MIR217 (MicroRNA 217)
|
KRAS mutation
|
doxorubicin hydrochloride • Nerofe (84AA-API 14AA)
12ms
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P #immunotherapy for patients with high-relapse risk with #KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. @EileenMOReilly #ASCO23 #ASCO2023 #clinicaltrials #news https://t.co/ITEzfo6nRF (@imedverse)
12 months ago
Clinical • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
12ms
There’s going to be a lot of activity in the adjuvant space in #PancreaticCancer with different vaccine platforms & immune modulators. There’s a real potential here to delay or prevent recurrences. Hopefully we can expand beyond mutant KRAS/p53 as target antigens. #ASCO23 (@Aiims1742)
12 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
|
TP53 mutation • KRAS mutation
12ms
Abstract 2528: AMPLIFY-201, a 1st-in-human safety & efficacy trial of adjuvant ELI-002 immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated #PancreaticCancer & #ColorectalCancer. @EileenMOReilly & @DrShubhamPant 👉🏽 non-mRNA vaccine in adjuvant space. (@Aiims1742)
12 months ago
Clinical • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12
12ms
4/ #ASCO23 Abs9006 #LCSM 💡SCARLET: ✅ Sotorasib + platinum-doublet chemo shows promising results in chemo-naive, adv non-squamous NSCLC pts w/ KRAS G12C mutation (jRCT2051210086). 🔥 ORR: 88.9%, 6-mo PFS: 61.2%, 6-mo OS: 87%. ⚠️ AE: Mostly manageable hematological toxicities.… https://t.co/xTQFTNwxbf (@ADesaiMD)
12 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
12ms
Our experts will present their latest research at #ASCO23, including studies of acute lymphoblastic leukemia, KRAS G12C-mutated tumors and racial disparities in GI cancers. Learn about them here: https://t.co/PUUSItVLBL @DrShubhamPant @ColonCancerDoc @ASCO #EndCancer (@MDAndersonNews)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
12ms
This KRAS mutant #colorectalcancer survivor is also excited to see everyone at #ASCO23 🤗 (@stacy_hurt)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
almost1year
Interesting findings which confirm retrospectively the increase risk of severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer @JTOonline https://t.co/FliPTNynCM (@LuisLara_M)
almost 1 year ago
Retrospective data • Adverse events
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
1year
Getting great information from @Benjohnson1112 about what is new in young onset #colorectalcancer from an oncology perspective! ✅YOCRC biology differs based on race and sex ✅No significant difference in KRAS, NRAS mutations in YOCRC #crcsm #ayacsm #cancer @MDAndersonNews (@ARosen380)
1 year ago
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS mutation • NRAS mutation
1year
📢 Our work just out @JTOonline "Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer" @OncoAlert @IASLC @OncBrothers https://t.co/fyOITTqHpz (@MDuruisseaux)
1 year ago
Adverse events
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
1year
40 M, met colon cancer, right sided On Folfox + bev NGS with BRCA2 + KrasG12D mutation No trial available Upon progression Tx? Of Label PARP? FOLFIRI+ Bev/Rami Other? (@BijoyTelivala)
1 year ago
Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase) • BRCA2 (Breast cancer 2, early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
KRAS mutation • KRAS G12D • KRAS G12
|
5-fluorouracil • irinotecan • leucovorin calcium
1year
Our clinical trial of Adagrasib in KRAS G12C mutant #PancreaticCancer is open & enrolling at @MDAndersonNews. It is led by Dr. @DanZhaoMD and will be accompanied by extensive tissue & blood based correlatives. @DrShubhamPant @break_cancer @letswinpc https://t.co/gPUKFejyck (@Aiims1742)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
1year
🔥🔥🔥Less than a month from ➡️@ASCO Plenary presentation ➡️@JCO_ASCO publication #Adagrasib is part of the @NCCN guidelines for patients with #PancreaticCancer and 🎯 #KRAS G12C mutation (@DrShubhamPant)
1 year ago
Clinical • NCCN guideline
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login